【Can-Fite BioPharma-Product CF102】Can-Fite BioPharma Announces Late-Breaking Abstract Presentation on Namodenoson Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting

Partner News

10th April 2019 – Can-Fite BioPharma Limited issued an announcement, which is summarized as follows:

*Acceptance for late breaking oral presentation underscores the oncology community’s interest in Namodenoson as a potential treatment for liver cancer

*Can-Fite now preparing for Phase III study of Namodenoson in patients with advanced liver cancer Child Pugh B 7 cirrhosis with Key Opinion Leader as Principal Investigator

“We consider ASCO’s acceptance of our late breaking oral presentation a testament to the compelling data coming out of our recently completed Phase II study of Namodenoson. We believe this reflects the oncology community’s assessment that our Phase II Namodenoson trial is a high-impact study with significant relevance in the treatment of liver cancer.” stated Can-Fite BioPharma Limited CEO Pnina Fishman.

Can-Fite is currently designing and planning the protocol for a Phase III study with the support of the world’s leading oncologists and regulatory experts including Dr. Josep Llovet, Founder and Director of the Liver Cancer Program and Full Professor of Medicine at the Mount Sinai School of Medicine, New York, a key opinion leader who will serve as the Phase III study’s Principal Investigator.

The original website link: